Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Randomized, Controlled Phase II Study to Evaluate the Efficacy and Safety of Afatinib Versus Irinotecan as a Second-line and Above Treatment for Advanced ALTRK-negative ESCC

NCT05818982 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT05818982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05818982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Randomized, Controlled Phase II Study to Evaluate the Efficacy and Safety of Afatinib Versus Irinotecan as a Second-line and Above Treatment for Advanced ALTRK-negative ESCC
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Unknown status
Start date
February 9, 2023
Completion date
February 28, 2026
Enrollment
72 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced esophageal squamous cell carcinoma